Beta Bionics, Inc. (NASDAQ:BBNX) Sees Large Decline in Short Interest

Key Points

• Short interest fell 43.1% to 6.05 million shares as of September 30, representing 14.2% of shares outstanding and a 3.3-day days-to-cover ratio.
• Insiders sold 97,697 shares worth approximately $1.91 million over the past three months, while several institutional investors—including Bank of America and Squarepoint Ops—opened new positions during the second quarter.
• Beta Bionics faces pending shareholder litigation alleging inadequate handling of safety complaints and FDA-related disclosures concerning its iLet system; the lead-plaintiff deadline is November 3, 2026. Despite the legal uncertainty, analysts maintain a “Moderate Buy” consensus with a $24 average price target versus a recent price of $17.22.

Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) was the recipient of a large drop in short interest in September. As of September 30th, there was short interest totaling 6,046,389 shares, a drop of 43.1% from the September 15th total of 10,617,768 shares. Currently, 14.2% of the company's shares are short sold. Based on an average daily volume of 1,859,712 shares, the days-to-cover ratio is currently 3.3 days.

Insider Transactions at Beta Bionics

In other Beta Bionics news, insider Steven Russell sold 4,221 shares of the business's stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total transaction of $80,663.31. Following the sale, the insider owned 169,628 shares in the company, valued at approximately $3,241,591.08. The trade was a 2.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Christy Jones sold 6,430 shares of the company's stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $23.00, for a total transaction of $147,890.00. Following the sale, the director directly owned 19,564 shares of the company's stock, valued at $449,972. This represents a 24.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 97,697 shares of company stock worth $1,907,034 in the last three months. Insiders own 5.30% of the company's stock.

Institutional Trading of Beta Bionics

Several large investors have recently modified their holdings of BBNX. Squarepoint Ops LLC bought a new position in shares of Beta Bionics in the second quarter worth about $2,524,000. Bank of America Corp DE bought a new stake in Beta Bionics during the 2nd quarter valued at approximately $8,566,000. Man Group plc bought a new stake in Beta Bionics during the 2nd quarter valued at approximately $419,000. Legal & General Group Plc bought a new stake in Beta Bionics during the 2nd quarter valued at approximately $62,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Beta Bionics in the 2nd quarter valued at approximately $172,000.

Key Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Negative Sentiment: The lawsuit alleges that Beta Bionics abandoned a safety feature in the iLet dosing algorithm and failed to investigate more than 18,000 customer complaints, including reports allegedly involving severe or life-threatening hypoglycemia. These claims have not been proven. SueWallSt Beta Bionics lawsuit notice
• Negative Sentiment: Investors are also alleging that company filings understated or omitted the significance of FDA concerns, including a June 2025 Form 483 and subsequent scrutiny of the iLet system’s quality controls and complaint reporting. Levi and Korsinsky Beta Bionics notice
• Negative Sentiment: The legal notices state that surprise revelations about FDA concerns contributed to sharp earlier declines in BBNX shares, with one firm citing a 37% drop and another alleging the stock had lost as much as 72% during the relevant period. The litigation creates potential legal costs, reputational damage and additional uncertainty regarding the company’s product and controls. Beta Bionics investor deadline notice
• Neutral Sentiment: Multiple firms, including Schall Brown & Schwartz, Pomerantz, Rosen, Kaplan Fox and others, are soliciting investors who purchased BBNX shares from July 30, 2025, through February 24, 2026, to seek lead-plaintiff status. The deadline is November 3, 2026; these announcements repeat the same pending case rather than reporting a new company operating update. Schall Brown and Schwartz Beta Bionics alert

Beta Bionics Stock Performance

Shares of Beta Bionics stock traded up $0.35 during midday trading on Thursday, reaching $17.22. 462,037 shares of the company's stock traded hands, compared to its average volume of 1,174,255. The company has a market cap of $774.73 million, a price-to-earnings ratio of -10.43 and a beta of 3.39. The company's 50 day simple moving average is $18.97 and its 200 day simple moving average is $15.14. Beta Bionics has a 52 week low of $8.80 and a 52 week high of $32.71.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.09. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. The business had revenue of $32.01 million during the quarter. As a group, equities research analysts predict that Beta Bionics will post -2.02 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on BBNX. Jefferies Financial Group initiated coverage on shares of Beta Bionics in a research note on Monday. They set a "buy" rating and a $30.00 target price on the stock. Weiss Ratings raised shares of Beta Bionics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, August 18th. Robert W. Baird increased their price objective on Beta Bionics from $14.00 to $16.00 and gave the stock a "neutral" rating in a report on Tuesday, September 15th. Barclays started coverage on Beta Bionics in a research report on Tuesday, October 6th. They set an "overweight" rating and a $30.00 price objective for the company. Finally, The Goldman Sachs Group boosted their target price on Beta Bionics from $17.00 to $19.00 and gave the company a "buy" rating in a research note on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $24.00.

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing and commercializing automated insulin delivery systems for people with insulin-requiring diabetes. Its lead product is the iLet Bionic Pancreas, an insulin pump system designed to automate much of the insulin-dosing process and reduce the daily burden associated with diabetes management.

The iLet Bionic Pancreas uses continuous glucose monitoring data and the company's dosing algorithms to deliver insulin. Unlike conventional insulin pumps that generally require users to calculate meal doses, the system is designed to simplify mealtime dosing by using a person's body weight and meal announcements as key inputs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.